VBI Vaccines Inc.

VBI Vaccines — World Vaccine Congress 2017

15 slides from VBI Vaccines's conference presentation, Apr 11, 2017

  1. Slide 1: Sci-B-Vac: Third Generation HBV Vaccine

    yyy, VBI VACCINES SCI-B-VAC: THIRD GENERATION HBV VACCINE WORLD VACCINE CONGRESS 2017, % amy NASDAQ: VBIV TSX: VBV APRIL 2017

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Information

    Cautionary Statement Regarding Forward-Looking Information Certain statements inthis presentation contain forword-looking statements within the meaning ofthe Private Securities Litigation Reform Act of 1995 or forword-looking information under applicable Canadion securities legislation (collectively

  3. Slide 3: Introduction to Sci-B-Vac

    Introduction to Sci-B-Vac™ Sci-B-Vac™ is a 3™ Generation HBV Vaccine Expressing All Major Surface Antigens of HBV — A Better Viral Mimic, Leads to Improved Potency + Inactivated HBV particles derived from serum of infected individuals Ba cenertion + Native human glycosylation BM Vaccines + Include H

  4. Slide 4: Aging Cohorts of Unvaccinated Adults Define Key Market Segments for an Improved HBV Vaccine

    Aging Cohorts of Unvaccinated Adults Define Key Market Segments for an Improved HBV Vaccine Universal Pedi ic Vaccination in 1990’s Still Leave Majority of Adults Exposed (Adult Vaccination Rates in US & EU = 20 - 24%) Market Segment Unvaccinated At-Risk Key Product Attributes Populations “ Obese, O

  5. Slide 5: The Unmet Need: High-Risk Populations of Non-Responders & Low Responders

    The Unmet Need: High-Risk Populations of Non-Responders & Low Responders to Yeast-derived, Alum Adjuvanted, HBsAg Vaccination EXEMPLAR SEROPROTECTION RATES: + Immuno-compromised © Patients with chronic liver disease ...... ~50% Chronic renal failure, dialysis & diabetes . aemeneamimnnenne signee tct

  6. Slide 6: Key Attributes of Sci-B-Vac

    ——— EEE Key Attributes of Sci-B-Vac Opportunity for an Improved HBV Vaccine in Adult Populations Improved Potency vs 2"¢ Generation Vaccines * Rapid Onset of Immunity * Potent in high-risk, non-responsive & immuno-compromised populations * Safe, well-known adjuvant: Alum Hydroxide * Exceptional Safe

  7. Slide 7: Sci-B-Vac Evokes Rapid Immunity — Recent Ph IV Study

    Sci-B-Vac Evokes Rapid Immunity — Recent Ph IV Study Showed Over 90% Sero-Protection After 2-Doses in Adults 18 - 40 Sci-B-Vac Phase IV Study in Israeli Adults (age 18-40, N=88) Seroprotection (>10 mIU/mL) 100.0% 98.8% 80.0% 91.9% 60.0% 56.8% 40.0% 20.0% 0.0% 1 (P1vd30) 2 (P2vd30) 3 (p2vd6o) Month C

  8. Slide 8: Opportunity for Improved Potency vs 2nd Generation Vaccines in Adult Populations

    Opportunity for Improved Potency vs 2"¢ Generation Vaccines in Adult Populations Additional Clinical Development to Define Benefits in Key Adult Populations Study 38-96-040: Sci-B-Vac Seroprotection and GMT vs Engerix-B (n = 524) in Adults Age 18 - 60 (mean age = 43) 100% 20% 20% 70% 60% 50% 40% 30%

  9. Slide 9: Older Adults are one Population that may Benefit from Sci-B-Vac

    Older Adults are one Population that may Benefit from Sci-B-Vac™: Superior Seroprotection Rates Stratification by Age of Study 38-96-040 Demonstrates Significantly Improved Potency in Older Adults Seroprotection Stratified by Age 100.0% 95.0% 90.0% 85.0% 20.0% 75.0% 70.0% 65.0% 60.0% 55.0% 50.0% Per

  10. Slide 10: Sci-B-Vac Offers Potential for Improved Potency in High-Risk Groups, Including Diabetics & CKD

    ee Sci-B-Vac Offers Potential for Improved Potency in High-Risk Groups, Including Diabetics & CKD Sci-B-Vac Stimulates Seroproective anti-HBsAg Immunity in CKD Populations That Had Not Responded to Double-Dose of Engerix-B Efficacy of Sci-B-Vac in Non-Responders: ‘Study of 16 Chronic Kidney Disease

  11. Slide 11: Data in Immuno-compromised: End-Stage Renal Disease

    Data in Immuno-compromised: End-Stage Renal Disease Investigator Led (T. Weinstein, 2004) Study at Rabin Medical Center, Israel Evaluated Seroprotection Rate of Sci-B-Vac™ in 29 ESRD Subjects — Notional Comparison Made to Historic Engerix-B® Responses in Same Department Sci-B-Vac Seroprotection (>10

  12. Slide 12: Synopses of Existing Clinical Studies for Sci-B-Vac

    ee Synopses of Existing Clinical Studies for Sci-B-Vac™ 22 clinical trials conducted to date 14 open label clinical studies + extension studies 5 observer blind clinical studies 9 of the above studies conducted in adults, 7 of which will be used to support a phase 3 Clinical Trial Application More t

  13. Slide 13: VBI is Discussing Its Clinical Development Priorities with Regulators

    ee VBI is Discussing Its Clinical Development Priorities with Regulators in North America & Europe EMA * Feb 2017: Received positive EMA Scientific Advice regarding Sci-B-Vac™ Phase III clinical program Health Canada * Feb 2017: Received positive response from Health Canada regarding Sci- B-Vac™ Pha

  14. Slide 14: Prophylactic Sci-B-Vac Summary

    ——— EEE Prophylactic Sci-B-Vac™ Summary OPPORTUNITY FOR IMPROVED POTENCY IN ADULT & AT-RISK POPULATIONS * Potent & Rapid HBV Immunity » Improved potency vs 2"4 generation HBV vaccines Rapid onset of immunity © Stimulation of immunity in non-responders tion in US/EU . History of safety with over 300,

  15. Slide 15: roi

    roi G =V = S SS Y KS VBI Vaccines, Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 NASDAQ: VAIV | TSX: VBV

VBI Vaccines — World Vaccine Congress 2017 on 6ix